Clinical trial results for pediatric ALCL
| Treatment strategy . | No. of patients . | Age, median (range), y . | Treatment duration (months) . | EFS (%) . | Study . |
|---|---|---|---|---|---|
| B-cell strategy with COPADM + maintenance | 82 | 10 (1.4-17) | 8 | 66 | Brugieres et al, 19989 |
| B-cell strategy with BFM-90 | 89 | 10.5 (0.8-17.3) | 5 | 76 | Seidemann et al, 20013 |
| B-cell strategy with COPADM | 72 | 11.8 (1.1-16.4) | 7-8 | 59 | Williams et al, 200216 |
| T-cell leukemia therapy | 34 | 11.6 (4.2-14.9) | 24 | 65 | Rosolen et al, 200515 |
| APO | 86 | NR | 12 | 72 | Laver et al, 200511 |
| Intensive T-cell strategy | 86 | NR | 12 | 68 | Lowe et al, 200913 |
| ALCL99 (B-cell strategy) | 352 | 11 (0.3-19.5) | 5 | 74 | Brugieres et al, 200920 |
| B-cell strategy BFM-95 | 32 | 10 (0.6-17.6) | 5 | 68 | Pillon et al, 201214 |
| APO with randomization of VBL | 125 | 11.9 (0.7-20) | 12 | 76 | Alexander et al, 20148 |
| Treatment strategy . | No. of patients . | Age, median (range), y . | Treatment duration (months) . | EFS (%) . | Study . |
|---|---|---|---|---|---|
| B-cell strategy with COPADM + maintenance | 82 | 10 (1.4-17) | 8 | 66 | Brugieres et al, 19989 |
| B-cell strategy with BFM-90 | 89 | 10.5 (0.8-17.3) | 5 | 76 | Seidemann et al, 20013 |
| B-cell strategy with COPADM | 72 | 11.8 (1.1-16.4) | 7-8 | 59 | Williams et al, 200216 |
| T-cell leukemia therapy | 34 | 11.6 (4.2-14.9) | 24 | 65 | Rosolen et al, 200515 |
| APO | 86 | NR | 12 | 72 | Laver et al, 200511 |
| Intensive T-cell strategy | 86 | NR | 12 | 68 | Lowe et al, 200913 |
| ALCL99 (B-cell strategy) | 352 | 11 (0.3-19.5) | 5 | 74 | Brugieres et al, 200920 |
| B-cell strategy BFM-95 | 32 | 10 (0.6-17.6) | 5 | 68 | Pillon et al, 201214 |
| APO with randomization of VBL | 125 | 11.9 (0.7-20) | 12 | 76 | Alexander et al, 20148 |
APO, doxorubicin, prednisone, vincristine, methotrexate, 6‐mercaptopurine; BFM, Berlin-Frankfort-Munster; COPADM, cyclophosphomide, vincristine, prednisone, doxorubicin, methotrexate; EFS, event-free survival; NR, not recorded; VBL, vinblastine.